… Non-small cell lung cancer (NSCLC) is one of the most … %, with no difference between second
and third-line or more (62… tumors, osimertinib was compared to gefitinib or erlotinib in non-…

… the survival data for erlotinib treatment beyond second-line therapy [14, … review of efficacy of
erlotinib or gefitinib compared to … of third-line chemotherapy in advanced non-small cell lung …

… has been demonstrated for many cancers, including non-small-cell lung cancer (NSCLC). …
as third-line therapy for patients with advanced NSCLC significantly prolonged PFS compared …

… pemetrexed + gefitinib (P + G) compared with gefitinib monotherapy. … Primary efficacy and
safety results of this study have been … tyrosine kinase inhibitors in non–small cell lung cancer …

… gefitinib and erlotinib with a median PFS of 10.2 months [12]. … the efficacy of third-line
chemotherapy, we assumed similar … osimertinib therapy was compared to EGFR TKIs gefitinib and …

… treatment comparisons within closed loops, namely erlotinib … patients with advanced
non-small-cell lung cancer previously … of erlotinib versus docetaxel as second- or third-line therapy …

… the efficacy of treatment with third-generation EGFR TKIs. … OS in the second-line and
third-line (or greater) cohorts was … resistance in comparison to erlotinib or gefitinib. Furthermore, …

… conducted to compare the relative efficacy of gefitinib, erlotinib, … NMA of the efficacy of first-line
gefitinib, erlotinib, afatinib, … the second- and third-line treatment strategies after TKI failure […

… to assess the efficacy and safety of EGFR-TKIs compared to … First-line erlotinib versus
gemcitabine/cisplatin in patients … comparing gefitinib with carboplatin-paclitaxel for chemo-naïve …

… study compared efficacy and toxicity of first-line treatment … with a significantly better PFS
compared to gefitinib, erlotinib, and … second- or third-line treatment. A previous study showed that …